US 12,303,533 B2
ECM hydrogel for treating esophageal inflammation
Stephen Francis Badylak, Lafayette, IN (US); Juan Diego Naranjo Gutierrez, Manizales (CO); and Lindsey Tamiko Saldin, El Segundo, CA (US)
Assigned to University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed by University of Pittsburgh—Of the Commonwealth System of Higher Education, Pittsburgh, PA (US)
Filed on Jul. 14, 2023, as Appl. No. 18/222,187.
Application 18/222,187 is a continuation of application No. 17/525,577, filed on Nov. 12, 2021, granted, now 11,707,485.
Application 17/525,577 is a continuation of application No. 16/490,054, granted, now 11,213,545, issued on Jan. 4, 2022, previously published as PCT/US2018/020758, filed on Mar. 2, 2018.
Claims priority of provisional application 62/465,985, filed on Mar. 2, 2017.
Prior Publication US 2024/0189349 A1, Jun. 13, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 35/12 (2015.01); A61K 9/06 (2006.01); A61P 1/04 (2006.01)
CPC A61K 35/12 (2013.01) [A61K 9/06 (2013.01); A61P 1/04 (2018.01)] 18 Claims
 
1. A method for inhibiting esophageal inflammation or reducing esophageal stricture in a subject, comprising:
administering to the esophagus of the subject a therapeutically effective amount of an extracellular matrix (ECM) digest solution comprising a hydrated, decellularized, enzymatically digested ECM derived from esophageal tissue, wherein the ECM has not been cross-linked or dialyzed, wherein the ECM digest solution has a pH of about 7.2 to about 7.8 and forms a gel when warmed to a temperature greater than 25° C.,
thereby inhibiting esophageal inflammation or reducing esophageal stricture in the subject.